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POLYMYOSITIS
Clinical investigation in two sisters
Margô Gomes de Oliveira Karnikowski1, Bruno Rodrigues Veloso Costa2,
Oscar Francisco Sanchez Osella3, Otávio de Tolêdo Nóbrega1
ABSTRACT - We present an investigation of a case of polymyositis affecting two sisters of one same parenthood.
Their cases have been documented for almost two decades, being investigated by means of a diagnostic
protocol which combined clinical findings as well as laboratorial, histopathological and image tests. In both
cases, clinical manifestations started in childhood, without signs of involvement of the central and peripheral
nervous system. Both patients proved to respond to a therapeutics based on corticosteroids. The degree of
relatedness between their parents corroborate the notion that genetic factors may contribute to the
development of the disease.
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Polimiosite: investigação clínica em duas irmãs
RESUMO - Apresentamos a investigação de dois casos de polimiosite, ocorridos entre irmãs de uma mesma
filiação. Seus casos foram documentados ao longo de quase duas décadas, tendo sido diagnosticados utilizando-
se de protocolo diagnóstico que combinou achados clínicos, exames laboratoriais, histopatológicos e por
imagem. Em ambos os casos, as manifestações clínicas se iniciaram ainda na infância, sendo constatada
ausência de acometimento do sistema nervoso central ou periférico. Ambas as pacientes responderam
satisfatoriamente a terapia baseada em corticosteróide. O grau de parentesco entre os genitores das pacientes
sugere que fatores genéticos podem predispor ao desenvolvimento da doença.
PALAVRAS-CHAVE: polimiosite, miopatia inflamatória.
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Idiopathic myopathies are a heterogeneous group
of acquired muscle diseases which affect 1 in
100,000 individuals1. Polymyositis (PM) comprises an
inflammatory myopathy that results from an abnor-
mal immune response to skeletal muscle fibers and
associated tissues. Activation of auto-reactive T-cyto-
lytic lymphocytes and molecular mimicry are proba-
ble mechanisms underlining this pathology2. More-
over, the majority of patients diagnosed with PM
display high levels of antibodies to self-antigens, such
as cell membrane components and nuclear pro-
teins3,4. Current diagnosis of PM is assessed by means
of compatible clinical findings (proximal muscle weak-
ness) and measurements of serum muscle enzymes,
electromyography and muscle biopsy5. Even though
causes for PM remain undetermined, an increasing
awareness that genetic factors are implicated has
evolved from different studies6,7. In spite of that, the
occurrence of more than one case within the same
family still consists in a rare event6,8,9.
This study has the purpose to describe anamne-
sis and testing procedures which resulted in the diag-
nosis of two patients with PM within the same paren-
thood, and to report treatment and evolution of both
patients documented over almost two decades.
CASES
Patient 1. G.R.V.C., 26 years old female Caucasian, dau-
ghter of parents related to the third degree, was born
presenting Apgar 10. The very first symptoms of mobility
disorder arose at the age of 5 years old as complaints of
strong muscular pains in both lower limbs after extenua-
ting physical exercises. At the age of nine, the patient
developed the habit of walking on her toe tips, what prom-
pted medical attention. Preliminary analysis revealed gene-
ralized hipotony, predominantly on the pelvic and scapu-
lar muscles. At this time, the following laboratorial tests
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were performed: complete hemogram (normal); summary
of urine (normal); oxalacetic transaminase 145 UI/l max
RV 30 UI/l; pyruvate transaminase 186 UI/l (max RV 37 UI/
l); lactate dehydrogenase 419 UI/l (max RV 240 UI/l); cre-
atine kinase (CK) 2,600 UI/l (max RV 70 UI/l); aldolase 26.3
UI/l (max RV 7.6 UI/l). X-ray analysis of the lumbar and the
sacrum-coccyx regions of the vertebral column yielded
normal results.
Studies on nerve-motor conduction revealed no altera-
tion on either latency or amplitude of the action potentials
of the nerves studied (median, ulnar and fibular), being the
speed of conduction preserved as well. Studies on sensitive
conduction of the same nerves have also failed to demon-
strate alterations. Nonetheless, quantitative electromyogra-
phy yielded motor units of greatly reduced length and am-
plitude, being polyphasic in their majority, mainly on the
biceps, deltoid and quadriceps muscles in spite of no signs
of denervation. Tomographic analysis failed to demonstrate
any intracranial expansive processes either above or below
the tentorium as well as absence of any pathological calci-
fications, attesting a cranium-encephalic status within the
parameters of normality. Additional tomographic analysis
revealed a similarly healthy vertebral condition, character-
ized by canal with dimensions and configuration compat-
ible with normality, lacking pathological compression upon
the dural sac. All findings above are consistent with a myo-
pathic condition of idiopathic etiology.
Biopsy of biceps and quadriceps were performed under
local anesthesia, being samples fixed before histological
processing. Both tissues revealed a degenerative process
characterized by disorganization of striated muscle fibers
with various degrees of atrophy, displaying multiple endo-
mysial infiltrates by polymorphonuclear cells. In some ar-
eas, intensive fagocytosis of muscle fibers by inflammatory
mononuclear cells could be observed, with signs of  bundle
regeneration and endomysial fibrosis. Such findings are
compatible with a myopathic condition of acute and
chronic polymyositis.
Patient 2. M.R.V.C., 23 years old, female, Caucasian,
sister of G.R.V.C., was born presenting Apgar 8. The first
symptom of mobility disorder arose at the age of nine, by
walking with her left foot in valgus. Having in mind her
sister’s condition, myopathy was taken under considera-
tion. At that time, the following laboratorial tests were
performed: complete hemogram with eosinophilia at 9%
(max RV 3%); oxalacetic transaminase 24.5 UI/l; pyruvate
transaminase 29 UI/l; lactate dehydrogenase 273 UI/l; cre-
atine kinase 1,580 UI/l; aldolase 19.7 UI/l. Max RV were as
cited previously. X-ray analysis of hands and feet revealed
osseous age within the normality. Similarly to her sister’s
case, studies of nerve-motor conduction have not shown
major alterations of either latency or amplitude of the ac-
tion potentials of the nerves investigated. Accordingly, elec-
tromyographic examination confirmed motor units of re-
duced length and amplitude, largely polyphasic and re-
stricted to the proximal muscles. Biopsies of these muscle
revealed an interstitial microscopic aspect similar to the
previous case, with several degenerative inflammatory ar-
eas and bundles being regenerated. On what concerned
its intensity, the degenerative process that was observed
in these samples exceeded the severity of the preceding
case, in spite of the lower levels of muscular enzymes. The
accentuated disappearance of the striated aspect and the
formation of large vacuoles in the muscle cells could trans-
late this increased myopathy. Both biochemical evidence
and histopathological findings attest an intense myopathic
process, greater in severity than the preceding case, and
consistent with acute polymyositis.
In both cases, initial therapeutics consisted on oral ad-
ministration of 60 mg of the corticosteroid prednisone
per day, which resulted in marked decrease of the serum
enzyme levels within the first month (Fig 1). Dosage was
gradually reduced according to the therapeutic response.
Nowadays, both patients present stable clinic conditions
which allow regular daily activities: walking without assis-
tance, absence of dysphasia and minor difficulty in shift-
ing from the seated to the ortostatic position. Both pa-
tients attend to physiotherapy sessions twice a week in
order to strengthen the pelvic and scapular musculature.
M.R.V.C employs a maintenance dose of  5 mg of corticos-
teroids in alternate days. G.R.V.C. sustains her medication
suspended since October/2000, following a 16 years period
of stable condition under administration of a similar main-
tenance scheme.
DISCUSSION
The first reports of polymyositis were based on
findings of anamnesis10,11. These studies used to ge-
nerate inaccurate diagnosis since inflammatory myo-
pathies share clinical symptoms such as mialgia, pro-
ximal muscle weakness and electromyographic al-
terations with several other idiopathic forms of myo-
pathy1,12. The development of diagnostic protocols
that couple laboratorial, histopathological and im-
age procedures has greatly facilitated the precise
identification of myopathies with inflammatory etio-
logy13,14, what in turn allows hiring an effective thera-
peutics. In this study, an investigation based on clini-
cal, biochemical and images findings was success-
fully hired to diagnose polymyositis in two non-twin
sisters from the same parenthood.
In both cases, the first clinical signs were observed
within childhood. In accordance to a typical myopa-
thic condition, levels of serum muscular enzymes (CK
and aldolase) were significantly elevated in preli-
minary tests. Electromyographic abnormalities con-
firmed a myopathic status which was not correlated
to any detectable cranium-encephalic or neurologi-
cal disturbances, whose normality was attested by
tomographic as well as nerve conduction analysis.
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Fig 1. Levels of the muscular enzymes CK (left axis) and aldolase (right axis) in the serum of both
patients, G.R.V.C. (A) and M.R.V.C. (B), throughout the treatment with corticosteroid. Each solid
line represents the union between independent dosages of CK (black line) and aldolase (gray
line) determined over the time. Horizontal dotted lines represent maximum referential values


































































































































































In addition, histopathological analysis of proximal
muscle biopsies of each patient revealed an intense
degenerative process characterized by marked in-
flammatory infiltrates, showing a clinical condition
compatible with PM. Nonetheless, symptoms usually
associated to inflammatory myopathies such as fever,
dysphasia and arthralgia12,13 have not been observed.
Exclusion of dermatomyositis (DM) was possible ba-
sed on the absence of cutaneous involvement in ei-
ther patients. Both cases proved to respond to a the-
rapeutics of corticosteroids, noticed the great reduc-
tion of the serum muscle enzymes within the first
month of treatment (Fig 1). In spite of the long-term
administration of steroids, periodic osseous densi-
tometry revealed no major pathological alterations
of their bone constitution.
Despite the fact that the etiology of PM remains
undetermined, different factors have been correlated
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with the origin of inflammatory myopathies. Some
studies implicate viral and bacterial infections as
possible triggering factor of the pathogenic pro-
cess9,15,16. Others enroll immune disturbances and
genetic profiles as causative determinants for the
onset of PM and DM. In the latter, disruption of im-
munological tolerance is considered a factor that
probably accounts to the development of muscular
lesions, since such lesions may consist in a patho-
logical outcome of the autoantibodies found in a
significant number of patients with PM6,17. In addi-
tion, the augmented frequency of the HLA-B8 and
DR3 haplotype among patients diagnosed with this
pathology suggests that a genetic profile may pre-
dispose to the its onset18. In the present study, both
patients are sisters from one same parenthood, whe-
re the parents are cousins in first degree. It is note-
worthy that related individual share sets of haplo-
type and that, for this reason, consanguine unions
tend to predispose their descendants to the onset
of recessive and multifactorial phenotypes. Thus,
even though a definitive relationship between im-
munogenetic factors and polymyositis has not been
established, we consider that the cases reported in
this study corroborate such an association.
The comprehension that the immune system
works as an agent that ensures the equilibrium within
the organism implies that its disturbance allows or
generates unbalance. In autoimmune diseases, it is
desirable to apply medicinal treatments that contri-
bute to the recovery from the unbalanced state. In
the cases above, treatment with corticosteroid pro-
ved to be appropriate for such purpose, considering
that patient G.R.V.C. remains with a stable condi-
tion despite of having her medication suspended for
one year. Nonetheless, it is important to emphasize
the need for an early and accurate diagnosis of in-
flammatory myopathies, so that an appropriate
therapeutics may take place around the dawn of the
pathological process to allow satisfying outcomes,
similar to those described in this study.
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